UMECRINE COGNITION - Key Persons
Born 1964. CEO from September 1, 2022.
Education: Holds an MBA from Henley Business School, University of Reading, UK. Management education from the London Business School and Harvard.
Experience: Anders Karlsson has extensive experience in leading operational roles and board work within the Swedish and international life science industry. After being CEO of Novartis' Norwegian operations 2003-2006, where he among other things was responsible for the commercialization of CNS drugs, he has held the role of CEO at the medical technology companies Absorber, Olerup International, Olerup SSP 2007-2011, and Allenex (Nasdaq Small Cap) 2011-2016. He has also been responsible for the global operations, outside North America, in the US-listed (Nasdaq) diagnostic company CareDx Inc. 2016-2019.
Before joining Umecrine Cognition Anders held the role as CEO för Idogen AB, a cell therapy company listed on Nasdaq First North (2019-2022).
Job Titles:
- Member of the Board of Directors
- Non - Executive Director
- Consultant to Ocelot
Born 1946. Board member since 2016.
Education: Bruce holds a Bachelor of Medical Sciences from the Northwestern University and an M.D. from Northwestern University - Feinberg School of Medicine.
Experience: Bruce has held senior management positions at Chiron, Novartis and most recently Hyperion Therapeutics, where he was Chief Medical and Development Officer. Prior to joining the industry, Bruce was Professor of Medicine and Chief of Gastroenterology at the University of California, San Francisco, and served as Editor-in-Chief of the Journal of Clinical Investigation and President of the American Society for Clinical Investigation. He has authored over 200 research and review articles and is inventor on multiple issued and pending patents.
Other current assignments: In addition to Umcrine Cognition, Bruce is a consultant to Ocelot Bio, Poseida Therapeutics (PSTX) and Venrock Capital.
Holdings in the company: Bruce F. Scharschmidt has an indirect holding of 132,725 shares through The Bruce Frederick Scharschmidt and Peggy Sue Crawford Family Trust Dated October 9, 2021.
Born 1968. CFO since 2021.
Education: Hans Christopher has an M.Sc. in Economics from the Stockholm School of Economics.
Experience: Hans Christopher "HC" Toll has previous experience as CFO for companies within several industries since 2004, such as Portescap SA and KIN Group, and currently has consulting assignments for companies such as Cedergrenska AB, EcoBloom Sweden AB, Yabie AB and WeHype Global AB. Furthermore, he has experience from previous listings, and was during 2016 CFO for AIK Fotboll AB when it was listed on NGM, and assisted in the listings of FundedByMe and Cedergrenska AB on Nasdaq First North Growth Market.
Job Titles:
- Member of the Board of Directors
- Non - Executive Director
Born 1971. Board member since 2020.
Education: John has an M.D. from Linköping University and a Ph.D. from Lund University.
Experience: John has broad knowledge and experience of drug development in several therapeutic areas, including CNS, cancer and blood disorders. He has held leadership roles within the research organizations of AstraZeneca, Shire Pharmaceuticals and Medivir. Before joining Karolinska Development he was the Chief Medical Officer of Modus Therapeutics. Prior to his drug development roles, John held various research and clinical positions at Lund University and Karolinska Institutet/University Hospital.
Born 1957.
Education: Lars holds an MBA from the Stockholm School of Economics.
Experience: Lars Öhman has more than 25 years wide-ranging research and business experience in senior positions at Karo Bio AB and Pharmacia. Proven track record in drug discovery and business development within the pharmaceutical industry. Responsible for in- and out-licensing of drug discovery and development projects to the pharmaceutical industry at Karo Bio during 2004-2012.
Job Titles:
- Chief Scientific Officer
- SVP
Born 1967. CSO since 2022.
Education: Magnus has a master's degree in organic chemistry and a Ph.D. in biotechnology from the Royal Institute of Technology in Stockholm and an Executive MBA from Stockholm Business School, Stockholm University.
Experience: Magnus Doverskog has more than 20 years industry experience from discovery and development projects of both small molecules and biologics. Senior positions at Astra Pain Control, Biovitrum AB, and as CEO of IMED AB. Post doctorial research at the European Molecular Biology Laboratory (EMBL) in Heidelberg where he obtained a Marie Curie individual Fellowship. Magnus also held the role as CEO of Umecrine Cognition between 2012-2022.
Job Titles:
- Member of the Board of Directors
- Non - Executive Director
Born 1949. Board member since 2017.
Education: Thomas holds a Master of Philosophy from Nottingham University, and a Ph.D. and D.Sc. from the University of Manchester.
Experience: Thomas brings more than 40 years of experience in the pharmaceutical and biotechnology sectors, where he has held senior management positions at major pharmaceuticals, such as ICI, Beecham/SmithKline Beecham, and biotech companies such as Synaptic Pharmaceutical Corporation and Helicon Therapeutics, and previously served as a board member of Motac Neurosciences Ltd. He is President Emeritus of the British Pharmacological Society and Business Advisor for Phyzat Biopharmaceuticals. He has authored more than 100 scientific papers and book chapters and is currently Reviews Editor for the British Journal of Pharmacology, as well as the inventor/co-inventor on 22 patents.
Job Titles:
- Founder
- Member of the Board of Directors
- Non - Executive Director
- Professor at the Department of Clinical Science
Born 1948. Board member since 2006.
Education: Torbjörn has an M.D. and a Ph.D. from Umeå University.
Experience: Torbjörn is currently professor at the Department of Clinical Science, Obstetrics and Gynecology, Umeå University. He is also head of the Umeå Neurosteroid Research Center. Professor Bäckström's main focus of research since 1972 is the effect of sex and stress hormones on the brain and conditions induced by these hormones, he has more than 400 scientific publications within this area and he is a frequently invited key-note speaker at scientific meetings around the world.
Job Titles:
- Chairman of the Board of Directors
Born 1965. Chairman since 2019 and board member since 2016.
Education: Viktor has an M.D, a Ph.D. and an Associate Professor degree from Karolinska Institutet.
Experience: Viktor has over 19 years of venture capital experience focused on life science with several investments, significant fundraisings, exits and IPOs. He was responsible for Life science at SEB Venture Capital during the years 2002-2016. During his appointment at SEB Venture Capital he also served as a board member in several biotech and medtech companies. Prior to this, Viktor worked as Associate Professor and senior consultant at Karolinska Institution/hospital in Huddinge. He also has significant experience from pre-clinical and clinical research within different biotech and medtech companies.